Medprin Regenerative Medical Technologies Co. Ltd. (301033) - Net Assets
Based on the latest financial reports, Medprin Regenerative Medical Technologies Co. Ltd. (301033) has net assets worth CN¥716.31 Million CNY (≈ $104.82 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥805.10 Million ≈ $117.81 Million USD) and total liabilities (CN¥88.79 Million ≈ $12.99 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medprin Regenerative Medical Technologie liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥716.31 Million |
| % of Total Assets | 88.97% |
| Annual Growth Rate | 18.23% |
| 5-Year Change | 106.96% |
| 10-Year Change | N/A |
| Growth Volatility | 25.09 |
Medprin Regenerative Medical Technologies Co. Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how Medprin Regenerative Medical Technologies Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Also explore Medprin Regenerative Medical Technologie (301033) total assets for the complete picture of this company's asset base.
Annual Net Assets for Medprin Regenerative Medical Technologies Co. Ltd. (2019–2024)
The table below shows the annual net assets of Medprin Regenerative Medical Technologies Co. Ltd. from 2019 to 2024. For live valuation and market cap data, see 301033 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥699.66 Million ≈ $102.38 Million |
+10.03% |
| 2023-12-31 | CN¥635.86 Million ≈ $93.05 Million |
+5.52% |
| 2022-12-31 | CN¥602.58 Million ≈ $88.18 Million |
+4.64% |
| 2021-12-31 | CN¥575.87 Million ≈ $84.27 Million |
+70.34% |
| 2020-12-31 | CN¥338.07 Million ≈ $49.47 Million |
+11.66% |
| 2019-12-31 | CN¥302.78 Million ≈ $44.31 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Medprin Regenerative Medical Technologies Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16889237789.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥158.20 Million | 22.61% |
| Other Components | CN¥541.46 Million | 77.39% |
| Total Equity | CN¥699.66 Million | 100.00% |
Medprin Regenerative Medical Technologies Co. Ltd. Competitors by Market Cap
The table below lists competitors of Medprin Regenerative Medical Technologies Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shandong Donghong Pipe Ind Co
SHG:603856
|
$540.27 Million |
|
Memsensing Microsystems Suzhou China Co Ltd
SHG:688286
|
$540.43 Million |
|
Suzhou Weizhixiang Food Co. Ltd.
SHG:605089
|
$540.59 Million |
|
Smartoptics Group AS
OL:SMOP
|
$540.62 Million |
|
HIMALAYA SHIPPING LTD DL1
F:J1X
|
$540.21 Million |
|
Shanghai Titan Scientific Co. Ltd. A
SHG:688133
|
$540.20 Million |
|
Cooper Stnd
NYSE:CPS
|
$540.05 Million |
|
Bumble Inc
NASDAQ:BMBL
|
$540.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medprin Regenerative Medical Technologies Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 635,858,213 to 699,664,693, a change of 63,806,480 (10.0%).
- Net income of 78,854,230 contributed positively to equity growth.
- Dividend payments of 27,135,621 reduced retained earnings.
- Other factors increased equity by 12,087,871.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥78.85 Million | +11.27% |
| Dividends Paid | CN¥27.14 Million | -3.88% |
| Other Changes | CN¥12.09 Million | +1.73% |
| Total Change | CN¥- | 10.03% |
Book Value vs Market Value Analysis
This analysis compares Medprin Regenerative Medical Technologies Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.23x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 9.12x to 5.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥6.04 | CN¥55.06 | x |
| 2020-12-31 | CN¥6.75 | CN¥55.06 | x |
| 2021-12-31 | CN¥8.66 | CN¥55.06 | x |
| 2022-12-31 | CN¥9.12 | CN¥55.06 | x |
| 2023-12-31 | CN¥9.63 | CN¥55.06 | x |
| 2024-12-31 | CN¥10.52 | CN¥55.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medprin Regenerative Medical Technologies Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.27%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.32%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.14x
- Recent ROE (11.27%) is above the historical average (8.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 9.26% | 24.44% | 0.33x | 1.14x | CN¥-2.22 Million |
| 2020 | 11.05% | 29.93% | 0.27x | 1.36x | CN¥3.52 Million |
| 2021 | 7.81% | 29.08% | 0.21x | 1.30x | CN¥-12.51 Million |
| 2022 | 5.96% | 18.38% | 0.26x | 1.24x | CN¥-24.37 Million |
| 2023 | 6.43% | 17.71% | 0.29x | 1.24x | CN¥-22.71 Million |
| 2024 | 11.27% | 28.32% | 0.35x | 1.14x | CN¥8.89 Million |
Industry Comparison
This section compares Medprin Regenerative Medical Technologies Co. Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,693,665,971
- Average return on equity (ROE) among peers: 12.72%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medprin Regenerative Medical Technologies Co. Ltd. (301033) | CN¥716.31 Million | 9.26% | 0.12x | $540.22 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $486.48 Million | 24.26% | 0.26x | $449.34 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $405.69 Million | 15.24% | 0.11x | $4.30 Billion |
| Double Medical Technology Inc (002901) | $3.16 Billion | 1.87% | 0.47x | $2.63 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $49.59 Million | 43.44% | 0.23x | $577.41 Million |
| Lepu Medical Tech Beijing (300003) | $6.01 Billion | 11.30% | 0.58x | $3.87 Billion |
| INKON Life Technology Co Ltd (300143) | $116.90 Million | 17.41% | 0.92x | $1.23 Billion |
| Edan Instruments Inc (300206) | $1.22 Billion | 8.49% | 0.19x | $1.26 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.39 Billion | -4.69% | 0.82x | $685.28 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.45 Billion | 0.44% | 0.18x | $534.16 Million |
| Sinocare Inc (300298) | $2.65 Billion | 9.46% | 0.24x | $1.36 Billion |
About Medprin Regenerative Medical Technologies Co. Ltd.
Medprin Regenerative Medical Technologies Co., Ltd. engages in the research, development, manufacture, and sale of implantable medical devices. The company offers artificial dura matermembrane patches, craniomaxillofacial repair and fixation systems, and absorbable regenerative oxidation for neurosurgery meningeal repair, skull repair fixation and rapid hemostasis, etc. It also offers ReDura, a S… Read more